FITCHBURG, MA, Sep 13, 2013 (Menafn - Marketwired via COMTEX) --Arrhythmia Research Technology Inc. (nyse mkt:HRT) (the "Company")announced today that the Company's Board of Directors appointed Mr.Derek T. Welch, age 45, the Company's Corporate Controller, to act asprincipal financial officer and accounting officer of the Companyupon the resignation, effective September 12, 2013, of Mr. David A.Garrison, who served as the Company's Executive Vice President andChief Financial Officer.<br /><br />"We are pleased to have Mr. Welch step into this role," said E.P.Marinos, the Company's Chairman of the Board. "His business,technical experience and proven work ethic will provide strength andleadership during this transition period."<br /><br />Mr. Welch has over 20 years of accounting experience across a varietyof industries including retail, management consulting, manufacturingand medical devices. His experience includes public reporting,acquisitions, Sarbanes Oxley compliance, budgeting and forecasting aswell as domestic and international systems implementations.<br /><br />Mr. Welch is a certified public accountant and earned his Bachelor'sDegree in Business Administration, with a concentration inaccounting, from the University of New Hampshire.<br /><br />About Arrhythmia Research Technology, Inc. The Company through itswholly-owned subsidiary, Micron Products, Inc. manufacturescomponents, devices and equipment primarily for the medical anddefense industries. Micron is engaged in the production and sale ofsilver/silver chloride coated and conductive resin sensors used ascomponent parts in the manufacture of integrated disposableelectrophysiological sensors. These disposable medical devices areused worldwide in the monitoring of electrical signals in variousmedical applications. The Company has expanded into customthermoplastic injection molded products with a full array of design,engineering and production services and management. The addition ofan orthopedic implant machining operation produces quick-turn, highvolume and patient-specific, finished orthopedic implants. TheCompany also has developed and distributes a customizable proprietarysignal-averaging electrocardiography (SAECG) software used in thedetection of certain heart arrhythmias and that is reconfigurable fora variety of hardware platforms.<br /><br />For more information please check our websites:<br /><br />http://www.arthrt.comhttp://www.micronproducts.com<br /><br />Forward-looking statements made herein are based on currentexpectations of the Company that involve a number of risks anduncertainties and should not be considered as guarantees of futureperformance. The factors that could cause actual results to differmaterially include our ability to maintain our current pricing modeland/or decrease our cost of sales; our ability to increase sales ofhigher margin products and services; variations in the mix ofproducts sold; variability of customer demand and deliveryrequirements; ability to license our software, provide timelycustomization and updates; a stable interest rate market and/or astable currency rate environment in the world, and specifically thecountries where we are doing business; continued availability ofsupplies or materials used in manufacturing at competitive prices;continued availability of supplies or materials used in manufacturingat competitive prices; amount and timing of investments in capitalequipment, sales and marketing, engineering and informationtechnology resources; volatility in commodity and energy prices; andthe Company's ability to offset higher costs with price increases.More information about factors that potentially could affect theCompany's financial results is included in the Company's filings withthe Securities and Exchange Commission, including its Annual Reporton Form 10-K for the year ended December 31, 2012.<br /><br /><br />Contact:<br />Investor Relations<br />(978) 602-1436<br />Website http://www.arthrt.com